[From histology via genetic signature to an improved treatment of breast cancer patients].
Today, breast cancer prognosis and (neo-) adjuvant treatment selection are based on clinical as well as on histological and immunohistochemical data. Will genetic expression profiles have a better predictive value? Ongoing studies will provide the answer.
Lehr
Hans-Anton
HA
Institut universitaire de pathologie, CHUV, Lausanne.
Delaloye
Jean-François
JF
Bosman
Frederik T
FT
D001943:Breast Neoplasms / Q000235:genetics / Q000473:pathology* / Q000628:therapy*; D005260:Female; D006801:Humans; D018570:Risk Assessment